Sanderling is investing in today's seeds for tomorrow's harvest; is your technology the next bumper crop?
Since 1979, Sanderling has been dedicated to building new biomedical companies, utilizing a unique approach of specialized investment focus, active managing and long term commitment. Sanderling has supported over 90 biomedical companies from very early stage start-ups, through commercial development.
Investments are made at all stages with a focus on ground breaking early stage technologies that reduce costs in hospitals. Currently they are investing Sanderling VII which closed in 2015. Investment areas include:
- Small molecule therapeutics
- Biologics and vaccines
- Drug delivery
- Platform technology
- Medical devices
Sanderling Venture Partners Louise Proulx and Michael Dixon will be in attendance to give an overview presentation about the company's key areas of interest. Following the presentation, don't miss this opportunity to introduce yourself to Louise and Michael during the networking lunch. And finally, for those companies who applied online and are approved, one-on-one meetings with Sanderling will provide an intimate forum to discuss your company.
10:30am | Registration Opens and Networking
11:00am | Presentation and Q&A
11:45am | Networking Lunch
1:00-5:00pm | One-on-one Meetings*
*Companies must have applied for a one-on-one meeting ahead of time and been approved. The application period ended on September 15th.
Sanderling Ventures Participating Representatives:
Michael Dixon | Venture Partner, Sanderling Ventures read bio»
Louise Proulx | Venture Partner, Sanderling Ventures read bio»
Presentation & Lunch
$25 | General Public
$35 | Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on October 17th (or sold out).
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period ended on September 15th. Your application will be reviewed and you will be notified of acceptance by email. Acceptance of one-on-one meetings is not guaranteed as all applications must be approved.
About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, NCI, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCATS, NINDS, Johnson & Johnson Innovation, Poliwogg, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.
Sanderling Ventures Participating Representatives' Biographies:
Michael Dixon, CPA | Venture Partner, Sanderling Ventures
Michael Dixon, CPA CA has over 18 years of experience working in an executive role for venture-backed companies. As CEO of Therillia Development Company Inc., Mr. Dixon oversees the development of therapeutic assets of interest to Therillia's shareholders, including dalcetrapib. Prior to his role in Therillia, Mr. Dixon was Chief Financial Officer of Gemin X Pharmaceuticals. At Gemin X he structured and negotiated equity financings leveraged with venture debt and other forms of non-dilutive capital to fund the company's Canadian and US operations over an 11-year period. Gemin X was successfully sold to Cephalon (now Teva), at the time one of the largest private biotech deals in Canada. Prior to Gemin X, Mr. Dixon was Interim COO and Vice President Finance at Morphometrix Technologies, a medical device company specialized in the automation of cervical cancer screening. Mr Dixon began his career at Price Waterhouse with a focus on compliance services for entrepreneurial businesses, strategic financial modeling and management information systems. Mr. Dixon received his Bachelor of Commerce degree from the University of Toronto and his Chartered Accountant designation while at Price Waterhouse.
Connect with Michael :
Louise Proulx, Ph.D. | Venture Partner, Sanderling Ventures
Louise Proulx holds a Ph.D. in physiology from Université Laval and pursued postdoctoral studies at the Karolinska Institute in Stockholm. She has close to 30 years' experience in research and development management. She has held, over the years, scientific positions of increasing responsibilities, notably as Vice President, Scientific Affairs at Hoechst Marion Roussel Canada, Vice President, Therapeutic Product Development at BioChem Pharma Inc., Vice President, Business Development of Genome Quebec and Vice Principal Research at McGill University. She then returned to the pharmaceutical industry where she has been Vice President, Product Development at ViroChem Pharma Inc. She then became Vice-President, and Site Head, at Vertex Pharmaceuticals (Canada) Incorporated after the acquisition of ViroChem Pharma by Vertex Pharmaceuticals. As Chief Development Officer at Therillia Dr. Proulx oversees the development of therapeutic assets of interest to Therillia's shareholders, including dalcetrapib. Dr. Proulx has been a member of several boards of directors over her career and she is currently a member of the board of directors of the Research Institute of the McGill University Health Center, Gestion Univalor, Verlyx Pharma and CQDM. Dr. Proulx is certified ICD.D by the Institute of Corporate Directors. She is also member of the Canadian Foundation for Innovation.
Connect with Louise:
Havana Room, 5th Floor
When & Where
JLABS, part of Johnson & Johnson Innovation, LLC, is a network of life science incubators providing emerging companies many of the advantages of being in a big company, without the capital investment. JLABS offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Companies residing at JLABS also have access to core research labs hosting specialized capital equipment and shared administrative areas. JLABS is an open innovation model, and the agreement for space does not grant JLABS or Johnson & Johnson Innovation any stake or rights in the companies, nor will the companies have a guaranteed future affiliation with JLABS. The flagship facility is located in San Diego at Janssen's West Coast Research Center, and JLABS has now two established locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility - one in Boston through a collaboration with Lab Central, one in Houston through a collaboration with TMC, and one in Toronto through a collaboration with MaRS. For more information please visit jlabs.jnjinnovation.com.